Landmark Study Suggests Single HPV Vaccine Dose May Offer Robust Protection
A groundbreaking U.S. government study has found that a single dose of the human papillomavirus (HPV) vaccine may be just as effective at preventing HPV infection as the traditional two-dose regimen, according to new data presented this week. The findings could dramatically reshape vaccination strategies worldwide, including policies and practices in Thailand, where increasing HPV vaccine uptake remains a crucial public health goal.
The new results, unveiled by U.S. government researchers, have been described by experts as “phenomenal,” underscoring the potential for a single-dose schedule to maintain protection against the most common and cancer-causing strains of HPV. The research, detailed in a highly anticipated STAT News report, adds to growing evidence that simplifying the HPV vaccine protocol could enhance global vaccination rates, lower health care costs, and ultimately save more lives.